



**SNO Digest**  
Weekly news from  
the Society for Neuro-Oncology

## WFNOS 2022 Was Successfully Held as an On-site and Virtual Meeting!




The 6th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies (WFNOS 2022) was successfully held in Seoul, Korea on March 24 - 27, 2022. Despite being postponed by a year, WFNOS 2022 could still not be held in person as planned due to safety concerns related to the continuation of the COVID-19 situation. As such, it was organized as a hybrid meeting that was attended in person by domestic participants and online by overseas participants. Although the hybrid format came with limitations in sharing the enthusiasm onsite, all the participants nonetheless were able to actively engage in and fully enjoy the meeting to gain the latest knowledge and information through such virtual components as live broadcasting consisting of four simultaneous sessions, live Q&A, and active communication via e-mail. [Read more.](#)

## Clinical Trials

### **Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma**

Building on NOA09, the NRG-BN011 phase III randomized clinical trial compares the combination treatment lomustine (CCNU) with temozolomide and radiation therapy versus temozolomide and radiation therapy alone for patients with newly diagnosed MGMT methylated glioblastoma. In addition to being an alkylator, CCNU introduces DNA interstrand crosslinks (ICLs), suggesting potential additive effects to temozolomide. The primary outcome for the study is overall survival. [Read more here.](#)

## From The Journals



### Prognostic factors related to overall survival in adolescent and young adults with medulloblastoma: a systematic review

Medulloblastoma is a rare diagnosis among adolescents and young adults (AYA). Though prognostic factors and treatment are well characterized among children with medulloblastoma, equivalent data for AYA are sparse. We conducted a systematic review to identify predictors of survival among AYA with medulloblastoma. [Click to read the full article.](#)

## Upcoming Webinar



The Society for Neuro-Oncology's Molecular Pathology Special Interest Track is pleased to announce the quarterly event for the SNO Pathology FAST (First Author Series Talk) webinar series. The webinar entitled Spatial Immunogenomic Heterogeneity of Malignant Brain Tumors will occur live on Monday May 16, 2022, at 1:00pm - 2:00pm EDT. [Click here to register.](#)

## Head to The Hill - Volunteers Needed

SNO members are encouraged to register to join the National Brain Tumor Society and their fellow advocates for Head to the Hill on May 2-3, 2022. All interested participants must register individually. Head to the Hill is our annual advocacy event where individuals help policymakers better understand the urgent, unmet needs of the brain tumor community. There are **both in-person and virtual participation** options this year. We are asking that members from, **Delaware, Kentucky, Alaska, Hawaii, Nebraska, Rhode Island, Wyoming, South Dakota, Wisconsin, Vermont, West Virginia, and Oklahoma, Idaho, Utah, Montana, North Dakota, Arkansas, and Mississippi** take the opportunity to register for this exciting event. For more information and to register, please [click here.](#)

## SNO Career Center



### This Week's Featured Listing

The Department of Translational Neurosciences at Pacific Neuroscience Institute is seeking candidates at the assistant, associate or full professor level for clinical faculty positions in Neuro-Oncology to join Dr. Santosh Kesari, MD, PhD, Founder of Pacific Neuroscience Institute, Chair and Professor of the Department of Translational Neurosciences and their growing team. [Click here to apply or see other postings!](#)

## [Upcoming SNO and SNO Affiliated Events](#)



## 2022 SNO Annual Meeting and Education Day - Call for Abstracts

Abstract deadline - June 1, 2022  
For information on the submission categories and requirements, please [click here](#).

To submit an abstract, please [click here](#).

## The 20th International Symposium of Pediatric Neuro-Oncology (ISPNO 2022)

June 12-15, 2022, in Hamburg

[Register Here](#)

**Early bird registration deadline: April 19, 2022**

For information about travel grants for LMIC countries, please [click here](#).



## 2022 SNO Introduction to Clinical Trial Design and Protocol Development Workshop

August 11, 2022

**Application deadline - April 15, 2022**

[Apply Here](#)

## 2nd Annual Conference on Clinical Trials and Brain Metastases

August 12-13, 2022

**Call for Abstracts - deadline: April 18, 2022**

[Submit Your Abstract](#)

## SNO Membership

It's Time to Spring Clean Your SNO Account!

Make sure you do not miss any important updates or journal deliveries from SNO by spring cleaning your SNO account today. Ensure your contact information is up-to-date and your membership is current by [clicking here](#) to log into your SNO account. Need assistance? Please contact Caroline Noor at [caroline@soc-neuro-onc.org](mailto:caroline@soc-neuro-onc.org) or 830.321.0615.

*SNO Digest is written and distributed by the Society for Neuro-Oncology. All content, including images, may not be reproduced unless permission is granted from SNO. If you would like to contribute to upcoming issues of the SNO Digest or if you have questions, please contact us at [snodigest@soc-neuro-onc.org](mailto:snodigest@soc-neuro-onc.org).*



27th Annual Meeting of the Society for Neuro-Oncology, November 16-20, 2022

Society for Neuro-Oncology | PO 273296, Houston, TX 77277

[Unsubscribe megan@soc-neuro-onc.org](mailto:megan@soc-neuro-onc.org)

[Update Profile](#) | [About Constant Contact](#)

Sent by [bysnodigest@soc-neuro-onc.org](mailto:bysnodigest@soc-neuro-onc.org) in collaboration  
with



Try email marketing for free today!